PRESS POINT OF THE PRESIDENT OF THE REPUBLIC AT THE END OF THE EUROPEAN COUNCIL

France Emmanuel Macron · President of France

25 March 2021 · End of the European Council

Context
Macron addressed a press point following the first day of the European Council videoconference on March 25, 2021, focusing on the EU's pandemic and vaccination strategy.
Main themes
European COVID-19 vaccination campaign, vaccine production acceleration, EU collective response to pandemic, export control mechanisms, vaccine delivery guarantees, EU-US convergence, HERA health emergency mechanism, vaccine contracts and industrial actors, pandemic preparedness, French vaccination commitments
Duration
~47 min
93rd percentile
Words
5,693
93rd percentile
Sentences
271
94th percentile
Readability
52
70th percentile
Grade
11.1
34th percentile
Syntax
2.99
46th percentile
Vocabulary
2.09
26th percentile

Translated from French

Content
Actors
Style

The broad sphere of national life a sentence belongs to. Every sentence has an Arena, so it is the denominator the other indices are read against.

Other
  • Social 35%33%
  • Economic 24%23%
  • Geopolitical 22%21%
  • Ceremonial 11%10%
  • Institutional 8%7%
  • Technological 0%0%
  • Environmental 0%0%
  • Not in focus 6%

271 sentences in 43 paragraphs

Good evening everyone. We have gathered for a new European Council via videoconference, the first day of which has just concluded with an exchange with the President of the United States, Joe BIDEN, which allowed us to highlight our important convergences as well as the challenges that lie ahead, foremost among them being the global response to the pandemic.

The main focus of this European Council discussion was obviously on the European fight against the virus, particularly the acceleration of our vaccination campaign so that we can return to a normal life as soon as possible. Our exchanges confirm this, and as you know, it is the conviction that France has held since the beginning: there is no other solution than a European solution to overcome this crisis. We can return to this if you wish, but this response is indeed European because we now have various and necessary capacities on European soil for the vaccine production cycle, whether it be the factories capable of ensuring their design or those responsible for what is called the bottling and finishing of doses. France hosts several of these, and together with the President of the Commission, Madam Ursula VON DER LEYEN, and the Commissioner in charge of this vaccine task force, Commissioner Thierry BRETON, whom I want to thank here for his work, we have examined in detail all the possibilities to immediately strengthen the European production of the vaccines we have ordered. This is the work we have focused on, which will allow us in the coming weeks to increase this European production and to be in a position in the very near future to produce entirely for ourselves and to be, by the summer, the continent that produces the most vaccines in the world.

This coordination will allow us to guarantee the delivery of vaccines and to ramp up to be quickly capable of producing several billion doses per year on our continent to meet the sustainable challenge posed by pandemics. It is a European solution because, I repeat, without a common purchasing mechanism, certain member states would probably not have been able to benefit from vaccine doses as quickly today. And a vaccination campaign in one or another country of the European Union would not make sense or be effective because we would have immediately, in a way, allowed the reinfection of the entire continent by the few unvaccinated countries. It was therefore important that we could focus on the common negotiation of these contracts with the producers, and it is indeed this European dynamic that must see its course through to the end.

In the same way, it is a European response that must be made to ensure that the rules of the game are respected and that all measures are taken to compel industrial actors who do not comply to do so. In this regard, we have supported — France has done so, collectively, we have done so — the measures taken by the European Commission to ensure more reciprocity and to truly activate the control mechanisms that were decided several weeks ago. Thus, doses that risked being diverted from their European production sites have been identified thanks to our export control mechanism. This is in no way protectionism. It is simply about preventing other developed countries from taking advantage of Europe while contracts signed between European countries and certain industrial actors are, to date, not being respected. Our citizens rightly expect that the vaccination campaigns we have decided upon, announced in our countries, are respected. And our duty is to ensure that we have such mechanisms in place to guarantee these doses.

Thanks to these efforts, we will be able to allow a large part of Europeans to obtain the promised doses in the coming days and weeks. I am particularly thinking of the doses expected from the AstraZeneca vaccine. Here too, I can provide you with all the desired details. And this is what will allow us to meet the commitments we have made and that I have reiterated several times, particularly the commitment, by the end of summer, to have offered all adult French citizens who wish to be vaccinated the opportunity to do so. For this, a significant increase in deliveries in the coming weeks and months is necessary, and the orders, as well as the mechanisms put in place by the Europeans, will allow this. This European approach is also what will enable us to continue producing more on our soil, which we have already begun to do, to finalize the two contracts that remain to be concluded with the companies Novavax and Valneva. It is also what will allow us to ensure the production on European soil of second-generation vaccines, that is to say, vaccines that will enable us to face the variants that will undoubtedly arrive next autumn and winter.

It is very important that, having learned from experience, we can position ourselves to respond to these challenges. In this regard, the European mechanism known as HERA, launched by the Commission, is absolutely essential. It has led to an initial investment of 50 million euros, which, in our view, must be supplemented. And it will also allow us to develop production capacities, as well as funding in terms of innovation to meet this challenge. Finally, the European response is also one that must allow us to take into account the interests of our neighbors and the poorest countries. That is why we are preparing together solidarity mechanisms to be able to share doses with countries in urgent need as soon as possible. I am thinking of both the Western Balkans and African countries, and you know the commitment we have made to provide the necessary doses to African healthcare workers. Europe will play its full role in this regard and will meet its responsibilities. Beyond this lengthy discussion we had on vaccines, which is, in my view, the heart of the battle we are fighting because, we can return to this if you wish to talk about France, but we are in a race against time between the third wave and the vaccination campaign across Europe. And this battle for vaccines is the battle we must win in the coming weeks and months. It is the one on which I am focusing all our efforts.

We also discussed the necessary coordination of European countries to prepare for reopening and, as soon as the pandemic has been slowed down, to enable us to have the tools to circulate again without threatening to spread the virus. This is the purpose of the European certificates that should allow everyone to prove that they are either vaccinated, tested negative, or have already been infected with the virus, recovered, and therefore have the necessary antibodies. I want to emphasize that this instrument is merely a medical proof harmonized across all member states, but it does not determine anyone's rights, which will be subject to national decisions. And we are also ensuring that the technology put in place fully respects the confidentiality of personal data and also the choices of each individual.

This European Council also allowed us to address several other topics, particularly those concerning our neighborhood, and we also discussed the issue of Russia and Turkey today. Regarding Russia, a topic we will return to at a future meeting, we reaffirmed our unity both to send messages of firmness, as was recently the case with the adoption of sanctions in response to the NAVALNY affair, and to outline the paths for necessary cooperation within the framework of a demanding dialogue. In this regard, we will continue to support civil society, which we cannot leave aside.

As for Turkey, we have noted positive advances from Ankara since our warnings at the European Council in December, as well as the necessity for these words to now be translated into action. In recent weeks and days, we have been able to build a European convergence and a unanimous position. It has been confirmed since no amendments to the text proposed by the President of the Council were submitted for discussion today. And we have decided, once again, as we did last autumn at France's initiative, on a two-step method: to set the conditions for a renewed Turkish-European engagement; and to give ourselves a meeting in June. This is what will allow us, I hope, to make progress in the stability of the Eastern Mediterranean, to advance in the essential dialogue between Greece and Turkey, to progress in the so-called 5+1 dialogue necessary for the UN process for Cyprus, and to also make progress in ensuring stability and a return to peace in Libya, which requires the withdrawal of all external forces, whether they be foreign fighters or Russian, Turkish armies, or external influences. In this context, I believe we have laid clear foundations, by the European Council in June, to allow Ankara to provide clarifications, to prove to us in the coming months its willingness to reattach itself to Europe. And if this is confirmed, several offers of rapprochement are on the table. But if we observe new forms of aggression, we can also very well reverse course. For my part, I hope that we can, based on this frank and lucid dialogue, re-engage on a path towards the future.

Finally, we discussed the internal market, industrial issues, and held a Eurozone summit with the President of the Eurogroup and the President of the European Central Bank. A few words on this subject. We obviously discussed the exit from the crisis, which involves maintaining budgetary support measures for as long as the health crisis lasts and the rapid implementation of the European recovery plan. The necessity of an adapted monetary policy, the need for investments in strategic priorities, and, fundamentally, to build in this context a strategic autonomy that must guide our industrial strategy to enable Europe to be both greener and more digital. But let us be clear, we provided an extremely strong response last July that complemented the monetary response. And I believe that in the first wave, the European Union provided a response that was up to the task, very clearly. We also have stabilization mechanisms that are linked to our models, which are much more resilient than those across the Atlantic or in other geographies. But the strength of the American response and the plan announced a few days ago by President BIDEN and his Congress places us before a historic responsibility. It is that following the second and third waves that the European Union has experienced, we will likely need to complement this response. In any case, we cannot be satisfied with a situation where — when I read the figures being reported, the European Union would take longer than other geographies to return to the trend it had before the pandemic. And therefore, in this regard, we will certainly need, in the coming weeks and months, to continue to think together and decide to have a just budgetary, strategic, and investment response to this crisis.

These are the few words I wanted to share to report on this Council, which, as I mentioned, concluded with an exchange with President BIDEN, where President Charles MICHEL, as the President of the Council, and Prime Minister COSTA were able to explain our strategy and also the necessity of a renewed dialogue between the European Union and the United States of America, which allowed us, in the face of the pandemic as well as the major international risks, to observe new convergences. These are the few words I wanted to share to report on this council, and I will now answer all the questions you may have.

Loïc SIGNOR

Good evening, Mr. President. Loïc SIGNOR, CNews. For the past four months, Europe has exported 77 million vaccine doses. During the same period, it has administered 62 million doses. Europe has therefore vaccinated less than it has exported. This is not really the Europe that protects that you are calling for, or else it is protecting other countries. Is there a risk of permanently marking the image of Europe among Europeans, but also, and particularly here in France, of an already criticized Europe?

Emmanuel MACRON

Thank you for your question. First of all, your question perfectly states that Europe is not a selfish continent. I think this is important because when I read the press across the Channel, we are put on trial every day, being told that it is the European Union that would be selfish. False. We have allowed value chains to operate as they existed. This is very important. But we noticed at the beginning of this year that the United States of America tended, within the framework of the structures that had been put in place, to protect the productions that were made in the United States of America to favor the American market, that the United Kingdom was not exporting many doses, to say the least, and so we established an export control mechanism.

Things then held up much better, and it is indeed this mechanism that shows its relevance in the situation we had to experience in Italy, where 29 million doses were seized and not exported. You are right to say that. The figures were made public this afternoon by the President of the Commission. Between December 1, 2020, and March 25, 2021, 77 million doses were exported. But what is this related to? First, to the proper functioning of things. Companies have global value chains. American companies sometimes finish their production in Europe for the European market, the American market, the British market. Should we have blocked all of this right away? No, that would have been a mistake. I remind you that we ourselves have also benefited from imports. We would not have a single dose of Moderna until now if we had not imported those doses produced outside the European Union.

We also produced doses that were exported to the poorest countries or those that needed these exports, which shows our solidarity, and it is necessary if we do not want other variants to develop that will then be re-imported, and we have also experienced this in the recent period. These variants sequenced in Brazil or South Africa re-imported and now spreading in our region show the necessity of vaccinating everywhere.

This situation fully justifies that we then put in place export controls, and I will not accept any moral trial, and it particularly justifies that we have differentiated dialogues with certain industrial players. Let’s be clear. Today, with Pfizer and BioNTech, we have had exports of doses produced on the European continent, but I note that all the contracts that have been made between the countries of the European Union and Pfizer BioNTech have been honored in amount, in volume, and on time. I note, modulo a few delays that I hope will be corrected very soon, that the contractual commitments we made with Moderna are being honored. But the contractual commitments we had with AstraZeneca have not been honored, and by a long shot. Here too, the elements that were made public by the European Commission this afternoon show it, and how much, and you have probably seen it. In the first quarter, out of the 100 million doses, compared to the 120 million doses that were agreed upon, only 30 million were delivered. And the deliveries are not meeting expectations, we have seen that again recently. And so faced with this situation, first a downward revision of the initial contractual commitments, then difficulties in delivering these commitments on time, it was necessary to put in place controls. That is what we have done, and I hope that the seizures that were made in Italy thanks to the cooperation of the Italian services, which I thank, will allow us to deliver on time to Europeans.

Now, the key, what is it? It is that we continue to accelerate, that we implement these mechanisms effectively, and that in relation to the contracts we have signed, we achieve results. I believe that it is Europe that protects. In relation to your question and the figures you mentioned since December 1, I note that some have gone faster than us. We will have to draw all the consequences from that. I see it as you do. I do not have, if I may say so, any false modesty. I believe that the United States of America have been more innovative, more ambitious, I have said it, perhaps they have been able to dream more than we have, and they have invested very significant sums to innovate faster and stronger. They were right. This should be a lesson. And so for second-generation vaccines, but also for other technological and scientific ambitions that Europe must have, we will need to somehow regain this taste for risk. That is the lesson we must take.

So, the two lessons I draw from the figure you provide are simple. First, the end of naivety. I support the export control mechanisms put in place by the European Commission. I support the fact that we must block all exports that will be made as long as laboratories do not respect their commitments to Europeans. And the second lesson is that we need to regain the taste for risk and investment in the future.

Ania NUSSBAUM

Good evening, Mr. President. A small question about Turkey. You mentioned in an interview with Greek television upcoming interference in the 2022 presidential election by the Turkish state. Can you explain what you meant? How should we interpret these comments in the broader context of a visibly renewed dialogue between the European Union and Turkey? May I also ask a very small additional question about the recovery plan and the need to strengthen the European Union's response in light of the American plan? Do you believe that the European Union should spend, at least in volume, as much as the Americans, as the United States?

Emmanuel MACRON

Regarding what I said about Turkey, there is nothing unspeakable, nothing inexplicable. It is an observation. There is today the existence of community organizations that have been very clearly explained, implemented. There is the existence of organized groups, the existence of political groups on the European continent that are today activated by official Turkish propaganda bodies, Diyanet among others. They are known and identified. They operate in Germany as well as in France. Sometimes they meddle in our elections. Other times, they interfere with the funding of associations. We have seen this again in recent days with the legitimate alerts made by the Minister of the Interior regarding some local authorities that may be a bit too complacent. When we have associations that admit they are unable to adhere to the values of the Republic, that is a problem. And so, there are all these forms of interference in the daily life of our democracy.

Then there are forms of interference through propaganda bodies that they broadcast on their channels. This is also identified. We experienced it last autumn. And so yes, the risks of interference are identified for the upcoming deadlines, just as these risks of interference have been identified in other European countries. They are organized and structured. It is a problem, and one cannot pretend to have a friendly relationship if we do not say things as they are and if we do not try to resolve them. France does not have a propaganda body. It does not fund associations, religious structures that operate in foreign countries or participate in the name of France in the elections of foreign countries. You would be shocked if that existed. It is normal that we are in a democracy like ours. Frankness imposes it, and we must address it.

Regarding the recovery plan, I want to be clear, the amounts are not comparable. Why? Because in the United States of America, there are no social safety nets that exist in Europe, and I would say particularly in France. There are not, in normal functioning, the redistributions that our public policies provide, which are somewhat equivalent to the amount of our public spending and redistributions, and therefore which are also a response to the crisis and to recovery, so we cannot compare everything. There is, in the American recovery plan, a lot that is on the demand side and not on the supply side and that compensates for the absence of solidarity policy in normal times in the United States of America. So, once that is taken into account, and the figures have been made public by both the OECD and the European Central Bank, to name just two organizations, the difference is smaller between the American recovery plan and the European recovery plan. Nevertheless, there is a difference. And when I also look at the trajectories over the coming years, it is clear that the United States of America will roughly regain the absolute level they had before the crisis by mid-2021, and especially will very quickly return to the trajectory that was theirs.

We will not regain that level until spring-summer 2022, but with a concerning trajectory lag because it represents a potential loss of growth, and this requires a response that is likely to be more vigorous. And I think this is the discussion we need to have among Europeans. How can we improve this response? How can we invest even faster and more strongly in our sectoral priorities? And beyond the amounts of investment, I believe very deeply, this is one of the lessons of the crisis, for Europe as well as for France, we need to drastically simplify our responses. We are too slow, we are too complex, we are too bogged down in our own bureaucracies. I believe we have all experienced this. We must go faster, stronger. That is a lesson we must all take.

Anthony LATTIER

Good evening, Mr. President, you have acknowledged a form of failure of Europe just now in the vaccine race, a lack of responsiveness, a lack of ambition at the outset. You mentioned that we need to draw all the consequences from that, what do you mean by that? And do you also recognize a form of failure of your health policy at the national level while the epidemic is exploding? Is there not, on your part, a form of stubbornness, as some doctors say, in not taking tougher measures?

Emmanuel MACRON

Well, I have not acknowledged a form of failure. I know that we have a tendency to love mea culpas. No. I try to be lucid. Many people believe that when one is determined, one should not recognize the situation as it is. That does not mean, however, that we do not look back at the past. So I try to be lucid. We reacted more slowly than the United States of America. That is a fact. However, I do not acknowledge failure because we corrected this delay very quickly. So we had a delay, it is true. If I did not dare to tell you that today, you would rightly say to me, “you lack lucidity,” and that would probably make the statements I will make less credible.

But I simply say, first, we recognized it, we repaired it. We put in place an export control mechanism. We are no longer naive. Second, we recognized it, repaired it, we accelerated production in Europe. And third, above all, I want to emphasize one point, the European Union has established a large-scale industrial policy to achieve a capacity of around 2 to 3 billion doses per year by the second half of this year. This means that we will be able not only to meet our needs but to export massively and sustainably. For our own European needs, we will deliver 360 million doses in the second quarter, nearly 420 by mid-July — I will not go into detail, we can do that if you wish — which will allow us to potentially achieve our continental herd immunity. That is to say, the delay we noticed at the beginning of the year, we made up for it very quickly in the weeks that followed, which puts us in a position, by mid-2021, to produce for ourselves and to produce enough to protect our fellow citizens and build our herd immunity.

Beyond that, Europe — and the figures cited by your colleague earlier show this — is the only continent that, in addition, exports. It is the only continent in the free world that has a real vaccination strategy and a real vaccine diplomacy. Not to blackmail one country or another, but to say this is an international commitment that is ours. And so it must be very clear, we are facing a global war of a new kind, particularly against the attacks and destabilization efforts from Russia and China through vaccine influence. In the face of this, if we want to hold our ground, we must be sovereign. We have positioned ourselves today to produce for this purpose. I will have the opportunity in the coming days to open production capacities in France that will complement those that French industrialists have also opened across Europe. And so, in light of this clarity I had earlier, our delays, our shortcomings at the very beginning, I believe that we have caught up and that we are responding to this crisis. This is the first point regarding production capacities, and thus Europe will truly be the continent that will produce the most doses in the world by the end of summer, will be in a position to cover itself, but also to export and to be the one that exports the most to its NATO partners, the free world, and all those in need. This is very important.

The second thing is that we are positioning ourselves to produce for second-generation vaccines. And that is at least as important. In the fall, in the winter, at the beginning of next year, we will likely again have variants of this virus, and these variants will lead us to have vaccination strategies once more. And I think it is very important that all our fellow citizens keep this in mind. We must act very quickly to vaccinate as soon as possible and protect ourselves against this virus. But it will continue to be there, circulating, mutating, and we will have responses to provide. What we are doing is also building our capacities to respond as quickly as possible as Europeans to these mutations. And that is very important.

Regarding the French strategy, which is no longer about the vaccine but about measures to slow down and respond to the crisis, first, we must always be very humble, and I have told you this from day one and up to the last months, I will always have the same humility. We do not know everything; we probably make mistakes every day. We try to do our best. The key is to correct our mistakes as quickly as possible. Should we have confined the country on January 29, as some said and as models showed that we would flare up in February? Listen, we have had the real collective experience, no. And so, I can tell you, we were right not to confine France at the end of January because there was no explosion as predicted by all the models. So I can assure you this time that I have no mea culpa to make, nor any regrets, nor any acknowledgment of failure. We were right to do it because we considered that it was a risk that was there, the virus was circulating, zero virus does not exist, it does not exist in any country in Europe. We are not an island, and even the islands that had protected themselves sometimes see this virus return. But we believed that, with the curfew measures that were taken and the slowing measures that were ours, we could cope without a flare-up. That is what happened.

From the beginning of March, and the inflection occurred between March 8 and 10, there was an acceleration that you saw in the incidence rates, and very quickly thereafter, quite surprisingly, in the entries into intensive care. And now, we see it, including in hospitalizations or calls to doctors. Things have accelerated. This corresponds to the fact that the variant, particularly the British variant, has become very predominant in several departments. And so we adapted our response by taking additional slowing measures, strengthening our capacity to test, alert, and protect. And last week, this led the government, after placing about twenty departments under enhanced surveillance, to take these slowing measures with very strong additional constraints: teleworking, constraints precisely in social life in 16 departments, which were supplemented this evening by the Minister of Health in 3 departments. This is pragmatism, it is pragmatism. And so, depending on the evolution of the epidemic, we adapt the response to be able to slow it down.

But you know, we need to take several factors into account: obviously, the dynamics of the Covid-19 epidemic; the other pathologies that are present; mental health, which also has consequences when we close, reduce social life, and isolate; the tension that exists and the difficulties for our young people for whom, in particular, these measures are very hard to live with; our educational priority which means that when we close, all this has consequences; and the economic and social consequences. It is always a balance that we maintain. And so I believe that we were right, on January 29, not to take closure measures, that we were right afterwards to implement the first slowing measures. And depending on the evolution of this epidemic, we will take all necessary measures in due time. And in my view, there are no taboos. We must always have the most appropriate response. But I also invite you to look all around us. You know, since mid-December, some of our neighbors have had very strong constraint measures. Since mid-December, Germany, our friend, our brother or sister in Europe, has had very strong constraint measures. Nurseries, schools are closed, everything is closed. And despite that, you have a resurgence of the epidemic that is linked to this increase in the variant, which also relativizes many of the comments I sometimes hear, and many of these constraint measures will be extended until April. This has educational and psychological consequences. And I respect this choice that has been made because the first wave was less severe. It is a balance to be struck. I think there is no simplistic answer in this context. We must all have a lot of humility, a lot of kindness, a lot of patience. What I want to tell you is that I will explain to you why we made these choices in due time.

Today, I look at the situation with a lot of concern, vigilance. Our emergency services are under very strong pressure, and so, in the coming days and weeks, what are we going to continue to do? To protect our most vulnerable fellow citizens who arrive in intensive care and whom we must protect, to protect our caregivers to enable them to face this challenge again, to do so under working conditions that I already know are difficult, and we will do everything to help them with the health reserve, with additional resources, but never put them in front of ethical choices that have never been ours. Then, continue to ensure the protection of other patients in France, particularly those who have heavy treatments, but also to take into account these other dimensions that I mentioned, namely mental health, the fatigue that exists in the country, the health of our young people, our children, the necessity to educate them, to allow them to be in a framework of development, and also the economic and social situation of the country. And so undoubtedly in the coming days, the coming weeks, we will have new measures to take. We will take them all together, in light of the facts, being transparent. We will do it in real time.

But I also want to give you, not a glimmer of hope but a reasonable perspective of hope, that we do have, thanks to the vaccination that we are going to deploy, safer milestones than a few months ago. By mid-April, we will have vaccinated 10 million of our fellow citizens, the oldest and most vulnerable, which means that 10 to 15 days later, they will be completely protected. And this is the overwhelming majority, if not three-quarters of our fellow citizens currently in intensive care, which means that starting from, you see, around April 20, we will reach a first milestone thanks to vaccination in terms of collective protection. Then, we will continue to vaccinate more and more. The supply will ramp up, and by mid-May, 20 million of our fellow citizens will have been vaccinated, meaning not only all those I just mentioned but the age group below, and 30 million by mid-June, which will allow us gradually — not only to relieve the pressure on intensive care services, but to enter the weeks, in a way, that will begin from the end of April and throughout May towards a gradual return and the steps that I will try to describe in the coming times to our fellow citizens. But we will be able to find a course, not because we will have regained control of time ourselves, but because thanks to vaccination, we will have reduced the control of the virus, so to speak, over our lives. The coming weeks will be difficult, we must be very clear-eyed, but the prospects that are ours thanks to vaccination should lead us to, together, do this with a lot of responsibility and mutual respect.

Unidentified speaker

Thank you. This concludes this press conference. Thank you to those who were present. Thank you, Mr. President.

Emmanuel MACRON

Thank you very much. Good luck to all.